Most patients were HIV-seropositive (170, 81%), with a median CD4+ T-cell count of 78 cells/μL (IQR 29–203 cells/μL); 94 (55%) of the HIV-seropositive patients were taking PCP prophylaxis, and 29 (17%) were taking antiretroviral therapy. Here, CD4 is linked to pneumocystosis.